Literature DB >> 25553994

Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.

Chang-Pan Liu1, Shou-Chuan Shih2, Nai-Yu Wang3, Alice Y Wu4, Fang-Ju Sun5, Shan-Fan Chow6, Te-Li Chen7, Tsong-Rong Yan8.   

Abstract

BACKGROUND/
PURPOSE: Identification of risks of mortality for carbapenem-resistant Acinetobacter baumannii (CRAB), with early implementation of an appropriate therapy, is crucial for the patients' outcome. The aim of this study was to survey mortality risk factors in 182 patients with CRAB bacteremia in a medical center in Taiwan.
METHODS: A total of 182 isolates of CRAB bacteremia were collected from 2009 to 2012 in Mackay Memorial Hospital, Taipei, Taiwan These isolates were identified by using the genotypic method. Risk of attributable mortality analysis was carried out with a Cox proportional hazards model.
RESULTS: The 182 CRAB isolates belonged to 38 different pulsotypes. The attributable mortality rate of the 182 patients was 58.24%. The risk factors for attributable mortality included intensive care unit stay [hazard ratio (HR): 2.27; p = 0.011], an Acute Physiology and Chronic Health Evaluation II score of >20 (HR: 2.19; p < 0.001), respiratory tract as the origin of bacteremia (HR: 3.40; p < 0.001), and previous use of ceftriaxone (HR: 2.51; p = 0.011). The appropriateness of antimicrobial therapy was 18.87% (20/106) in the mortality group versus 88.16% (67/76) in the survivor group (p < 0.001). The sensitivity of CRAB to colistin was 100% and to tigecycline was 40.11%.
CONCLUSION: The risk factors for mortality for CRAB included intensive care unit stay, a high Acute Physiology and Chronic Health Evaluation II score, respiratory tract as the origin of bacteremia, and previous use of ceftriaxone. Early implementation of an antimicrobial agent that had the highest in vitro activity against CRAB in patients at risk of CRAB bacteremia and high mortality may improve their outcome.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Acinetobacter baumannii, bacteremia; mortality; risk factors

Mesh:

Substances:

Year:  2014        PMID: 25553994     DOI: 10.1016/j.jmii.2014.10.006

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  19 in total

1.  Morbidity and mortality risk factors in emergency department patients with Acinetobacter baumannii bacteremia.

Authors:  Rui-Xue Sun; Priscilla Song; Joseph Walline; He Wang; Ying-Chun Xu; Hua-Dong Zhu; Xue-Zhong Yu; Jun Xu
Journal:  World J Emerg Med       Date:  2020

2.  Risk factors and clinical outcomes for intensive care unit patients with mul-tidrug-resistant Acinetobacter spp. bacteremia.

Authors:  Malbaša Đekić; T Dugandžija; G Dragovac; D Medić; M Paut Kusturica
Journal:  Hippokratia       Date:  2020 Jan-Mar       Impact factor: 0.471

3.  Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

4.  Colistin Dosage without Loading Dose Is Efficacious when Treating Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia Caused by Strains with High Susceptibility to Colistin.

Authors:  Rocío Álvarez-Marín; Rafael López-Rojas; Juan Antonio Márquez; María José Gómez; José Molina; José Miguel Cisneros; Carlos Ortiz-Leyba; Javier Aznar; José Garnacho-Montero; Jerónimo Pachón
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

Review 5.  Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.

Authors:  Eric Wenzler; Debra A Goff; Romney Humphries; Ellie J C Goldstein
Journal:  Infect Dis Ther       Date:  2017-03-04

6.  Risk Factors, Clinical Presentation, and Outcome of Acinetobacter baumannii Bacteremia.

Authors:  Tala Ballouz; Jad Aridi; Claude Afif; Jihad Irani; Chantal Lakis; Rakan Nasreddine; Eid Azar
Journal:  Front Cell Infect Microbiol       Date:  2017-05-04       Impact factor: 5.293

7.  Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment: A retrospective multicenter study in Korea.

Authors:  Tark Kim; Eun Jung Lee; Seong Yeon Park; Shi Nae Yu; Yu Mi Lee; Ki-Ho Park; Se Yoon Park; Min Hyok Jeon; Eun Ju Choo; Tae Hyong Kim; Mi Suk Lee
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

8.  Determinants of Mortality in Patients with Nosocomial Acinetobacter baumannii Bacteremia in Southwest China: A Five-Year Case-Control Study.

Authors:  Shuangshuang Yang; Jide Sun; Xianan Wu; Liping Zhang
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-06-03       Impact factor: 2.471

9.  Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia: A retrospective study from a Chinese hospital.

Authors:  Hua Zhou; Yake Yao; Bingquan Zhu; Danhong Ren; Qing Yang; Yiqi Fu; Yunsong Yu; Jianying Zhou
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

10.  Wide distribution of carbapenem resistant Acinetobacter baumannii in burns patients in Iran.

Authors:  Zahra Farshadzadeh; Farhad B Hashemi; Sara Rahimi; Babak Pourakbari; Davoud Esmaeili; Mohammad A Haghighi; Ali Majidpour; Saeed Shojaa; Maryam Rahmani; Samira Gharesi; Masoud Aziemzadeh; Abbas Bahador
Journal:  Front Microbiol       Date:  2015-10-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.